Human Papillomavirus 9-valent Vaccine, Recombinant
Human Papillomavirus 9-valent Vaccine, Recombinant is a biological therapy with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
4
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Clinical Trials (6)
Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6